IL6 and COVID-19: Maybe these two parameters (higher neutrophil count and NLR), which were proved to be laboratory indicators of severe COVID-19 due to cytokine storm leading to worse outcomes, could be prognostic factors for clinical response to treatment with tocilizumab in patients with high IL-6 concentration.